Oncternal Therapeutics Inc (ONCT) - Total Liabilities
Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has total liabilities worth $6.45 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Oncternal Therapeutics Inc (ONCT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Oncternal Therapeutics Inc - Total Liabilities Trend (1999–2023)
This chart illustrates how Oncternal Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Oncternal Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TNL Mediagene Ordinary Shares
NASDAQ:TNMG
|
USA | $49.03 Million |
|
Integrated Media Technology Ltd
NASDAQ:IMTE
|
USA | $1.99 Million |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
India | Rs7.39 Billion |
|
Lypsa Gems & Jewellery Limited
NSE:LYPSAGEMS
|
India | Rs503.60 Million |
|
Fsport AB
ST:FSPORT
|
Sweden | Skr1.12 Million |
|
Golden Cross Resources Ltd
AU:GCR
|
Australia | AU$10.33 Million |
|
Hynion AS
OL:HYN
|
Norway | Nkr29.09 Million |
|
Eurocell PLC
LSE:ECEL
|
UK | GBX195.90 Million |
Liability Composition Analysis (1999–2023)
This chart breaks down Oncternal Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Oncternal Therapeutics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncternal Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncternal Therapeutics Inc (1999–2023)
The table below shows the annual total liabilities of Oncternal Therapeutics Inc from 1999 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $6.68 Million | -13.08% |
| 2022-12-31 | $7.68 Million | +40.57% |
| 2021-12-31 | $5.46 Million | -6.71% |
| 2020-12-31 | $5.86 Million | -21.18% |
| 2019-12-31 | $7.43 Million | +42.65% |
| 2018-12-31 | $5.21 Million | -34.67% |
| 2017-12-31 | $7.97 Million | +72.96% |
| 2016-12-31 | $4.61 Million | -84.72% |
| 2015-12-31 | $30.17 Million | -8.07% |
| 2014-12-31 | $32.82 Million | +566.98% |
| 2013-12-31 | $4.92 Million | -51.15% |
| 2012-12-31 | $10.07 Million | +59.64% |
| 2011-12-31 | $6.31 Million | -49.61% |
| 2010-12-31 | $12.52 Million | -81.16% |
| 2009-12-31 | $66.47 Million | -12.64% |
| 2008-12-31 | $76.09 Million | -5.84% |
| 2007-12-31 | $80.81 Million | +150.93% |
| 2006-12-31 | $32.21 Million | +248.85% |
| 2005-12-31 | $9.23 Million | +0.64% |
| 2004-12-31 | $9.17 Million | -94.52% |
| 2003-12-31 | $167.54 Million | +156.42% |
| 2002-12-31 | $65.34 Million | +47.85% |
| 2001-12-31 | $44.19 Million | +55.79% |
| 2000-12-31 | $28.37 Million | +1611.89% |
| 1999-12-31 | $1.66 Million | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more